Drug intelligence / Profile preview

RENUBI Alpha

Development stage: Unknown
Lead developer: PICO Entech
Administration: Oral

Overview

RENUBI Alpha (리뉴비 알파) is a health supplement developed by PICO Entech, designed to support cognitive improvement and immune function. The product is formulated with a combination of Aldehyde Dehydrogenase (ALDH) dried yeast, phosphatidylserine, and zinc. ALDH is an enzyme involved in the metabolism of aldehydes, while phosphatidylserine is a phospholipid that plays a critical role in maintaining neuronal membrane integrity and supporting cognitive processes. Zinc is included as an essential mineral to promote normal immune system function. The supplement is marketed as a functional food product in South Korea.

Brand names: RENUBI Alpha리뉴비 알파
Other names: RENUBI Alpha리뉴비 알파

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)

Beyond the preview

Go deeper on RENUBI Alpha.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RENUBI Alpha.

Explore the full profile